Related Experiment Video
Updated: Jan 19, 2026
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
In vitro cytotoxicity screening to identify novel anti-osteosarcoma therapeutics targeting pyruvate dehydrogenase
Wei Cao1, Zhan Wang2, Xingwen Han3
1Clinical Laboratory, Beijing Rehabilitation Hospital, Capital Medical University, Beijing 100144, China.
Abstract:
Pyruvate dehydrogenase kinases (PDKs) act as negative modulator of mitochondrial pyruvate dehydrogenase complex (PDC) and play a crucial role in the regulation of oxidative glycolysis, which recently have been considered as a potential drug target for varying types of cancer and diabetes. Herein, we describe the discovery and biological validation of novel anti-osteosarcoma therapeutics targeting PDK2. We identified 14 anti-osteosarcoma compounds from an in-house small molecule library, which were then evaluated in a PDK2 kinase inhibition assay. We found that compounds with 2-((4-oxo-6-((4-phenylpiperazin-1-yl)methyl)-4H-pyran-3-yl)oxy)acetamide moiety showed promising inhibitory potencies to PDK2. Especial for 12, which bound to PDK2 with a Kd value of 2.3 µM, and inhibited PDK2 activity with an EC50 value of 1.1 µM. In addition, 12 selectively inhibited PDK2, the selectivity indexes are 10.6, 22.0, and 60.9 for PDK2 as compared to PDK1, 2 and 4, respectively. The MTT assay suggested that 12 reduced MG-63 cancer cell proliferation with an IC50 value of 4.7 µM. All these observations indicated that 12 was a novel anti-osteosarcoma therapeutic, which deserved for further investigation.
Insights
Researchers discovered novel therapeutics targeting pyruvate dehydrogenase kinase 2 (PDK2) for osteosarcoma treatment. Compound 12 demonstrated potent and selective PDK2 inhibition, reducing cancer cell proliferation.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Pyruvate dehydrogenase kinases (PDKs) regulate oxidative glycolysis and are implicated in cancer.
- PDK2 is a potential therapeutic target for various cancers, including osteosarcoma.
Purpose of the Study:
- To discover and biologically validate novel anti-osteosarcoma therapeutics targeting PDK2.
- To identify small molecules with potent and selective PDK2 inhibitory activity.
Main Methods:
- Screening of an in-house small molecule library against PDK2.
- Kinase inhibition assays to evaluate compound potency and selectivity.
- MTT assays to assess the effect of compounds on cancer cell proliferation.
Main Results:
- Identified 14 anti-osteosarcoma compounds with PDK2 inhibitory activity.
- Compound 12 exhibited strong binding (Kd = 2.3 µM) and inhibition (EC50 = 1.1 µM) of PDK2.
- Compound 12 showed high selectivity for PDK2 over PDK1, PDK2, and PDK4.
- Compound 12 significantly reduced MG-63 osteosarcoma cell proliferation (IC50 = 4.7 µM).
Conclusions:
- Compound 12 is a promising novel therapeutic candidate for osteosarcoma.
- Further investigation of compound 12 is warranted for its anti-cancer potential.
Related Concept Videos
08:04Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
02:58Evaluating Cytotoxicity and Membrane Integrity in Lung Slices via Lactate Dehydrogenase Assay
01:15Pyruvate Oxidation
First, the enzyme pyruvate dehydrogenase removes the carboxyl group from pyruvate and releases it as carbon dioxide. The stripped molecule is then oxidized and releases electrons, which are then picked up by NAD+...
13:01Anti-Nuclear Antibody Screening Using HEp-2 Cells
11:13Identification of Kinase-substrate Pairs Using High Throughput Screening
07:18A Simple Method to Identify Kinases That Regulate Embryonic Stem Cell Pluripotency by High-throughput Inhibitor Screening